: Ongoing heavy investment in the development of obicetrapib . Finance: New Amsterdam Invest N.V.

: The ship features a solarium with a retractable roof , allowing for swimming even in cold climates like Alaska .

: Recognized $22.5 million for 2025, down from $45.6 million in 2024, largely due to the timing of clinical development milestones .

: Passengers report exceptional service from friendly staff and high-quality food, especially in the Lido Market Buffet and main dining room .

: Total investment property stood at €118.0 million at year-end .

: Improved slightly to a net loss of $203.8 million for 2025, compared to $241.6 million in 2024 .

Recent reviews from 2026 highlight a sophisticated, mid-sized ship experience particularly well-suited for Alaskan cruises .